Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements: early-phase trial registry
4 of 4 indexed Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 4 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements: 4 US clinical trials tracked, 4 recruiting.
Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Yazeed Sawalha, running 1 of these trials.
Enrollment posture brief
Registry condition refractory-high-grade-b-cell-lymphoma-with-myc-and-bcl2-or-bcl6-rearrangements
OPEN 4 | RECR 100% | LATE 0 | EARLY 4 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements lists 4 open slots (100% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements is recruiting above its size-band peers.
4 of 4 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells
City of Hope Medical Center
NCT07042438
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
M.D. Anderson Cancer Center
NCT03136146
Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
Yazeed Sawalha
NCT06536049
Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma
Lapo Alinari
NCT05755087
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements page
4 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Yazeed Sawalha sponsors the most Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements trials on record, review their full trial history before evaluating a specific study. See Yazeed Sawalha's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements condition card totals 4 registered trials; most-linked intervention Biospecimen Collection; top US site state Ohio. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.